24 research outputs found
Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design
The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database
Tricuspid Annular Plane Systolic Excursion in Acute Decompensated Heart Failure: Relevance for Risk Stratification
Creating a Market Orientation: A Longitudinal, Multifirm, Grounded Analysis of Cultural Transformation
National Heart, Lung, and Blood Institute Working Group on Emergency Department Management of Acute Heart Failure
Assessing the Quality and Comparative Effectiveness of Team-Based Care for Heart Failure
Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee
Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties
Heart rate not only predicts outcome but may also be a therapeutic target in patients with chronic heart failure. Several classes of pharmacological agents can be used to modulate heart rate, including beta-blockers, ivabradine, digoxin, amiodarone, and verapamil. Choice of agent will depend on heart rhythm, co-morbidities, and disease phenotype. Beneficial and harmful interactions may also exist. The aim of this paper is to summarize the current body of knowledge regarding the relevance of heart rate as a prognostic factor (risk marker) and particularly as a therapeutic target (risk factor) in patients with chronic heart failure, with a special focus on ivabradine, a novel agent that is currently the only available purely bradycardic agent